Immunity and neuroinflammation in early stages of life and epilepsy
Epilepsia · 2025-07 · 66 (7) · 2157-2169
DOI: 10.1111/epi.18361 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsia, online erschienen am 12.03.2025. Verfasst von Angelica Vega García und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurological Diseases Medical Research Unit, Specialty Hospital, "Dr. Bernardo Sepúlveda", National Medical Center "XXI, Century", Mexican Social Sec…. Hauptthemen laut MEDLINE: Epilepsy, Neuroinflammatory Diseases, Brain. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
The immune system is crucial for the correct brain development, and recent findings also point toward central control of immune response. As the immune system is not fully developed at birth, the early years become an important window for infections and for the development of epilepsy. Both central and even peripheral inflammation may impact brain function, promoting opening of the blood–brain/blood and cerebrospinal barriers and allowing entry of immune cells and cytokines, which in turn may affect neuron function and connections. The resident brain immune cells, microglia, besides providing protection, also affect neurons, myelination, and astrocyte function. They may, via the complement system, remove synapses, both physiologically and pathologically. After seizures during development, activated microglia releases proinflammatory molecules, which are detrimental for neurons, and inhibition of microglial activation shows promising antiepileptogenic effects. In addition to cytokines, seizures and excessive excitability stimulate calpain 2 expression, which can promote neuron loss and contribute to amplification of inflammatory responses via stimulation of proinflammatory cytokines. In summary, the immature immune system during postnatal early life may be an important target for the development of long‐desired antiepileptogenic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurological Diseases Medical Research Unit, Specialty Hospital, "Dr. Bernardo Sepúlveda", National Medical Center "XXI, Century", Mexican Social Security Institute (IMSS), Mexico City, Mexico.
- Laboratorio de Epilepsia Experimental, Instituto de Investigaciones Cerebrales, Universidad Veracruzana, Veracruz, Mexico.
- Department of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.
- Pharmacobiology Department, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico.
- Departamento de Neurologia e Neurocirurgia, Escola Paulista de Medicina, Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil.
ORCID-Profile: María Leonor López-Meraz, Marco I González, Luisa Rocha, Jose Eduardo Peixoto-Santos, Esper Abrão Cavalheiro
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Vega García, A., López-Meraz, M. L., González, M. I., Rocha, L., Peixoto-Santos, J. E., & Cavalheiro, E. A. (2025). Immunity and neuroinflammation in early stages of life and epilepsy. Epilepsia, 66(7), 2157-2169. https://doi.org/10.1111/epi.18361
Vancouver
Vega García A, López-Meraz ML, González MI, Rocha L, Peixoto-Santos JE, Cavalheiro EA. Immunity and neuroinflammation in early stages of life and epilepsy. Epilepsia. 2025;66(7):2157-2169. doi:10.1111/epi.18361
BibTeX
@article{VegaGarca2025,
author = {Vega García, Angelica and López-Meraz, María Leonor and González, Marco I and Rocha, Luisa and Peixoto-Santos, Jose Eduardo and Cavalheiro, Esper Abrão},
title = {Immunity and neuroinflammation in early stages of life and epilepsy},
journal = {Epilepsia},
year = {2025},
volume = {66},
number = {7},
pages = {2157--2169},
doi = {10.1111/epi.18361}
}
EUVIMED